Fig. 4
From: Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
Correlation between percentages of CD4+CD26high and clinical benefit to nivolumab. Box plots showing the median (25th; 75th percentile) levels of CD26high cells in melanoma patients stratified in clinical benefit (CB) e no CB (NCB) groups at 12 months (A). Box plots showing the median (25th; 75th percentile) baseline frequencies of CD26high lymphocytes in CB and NCB subgroups of patients treated with 1st line nivolumab and 2nd/3rd line nivolumab at 12 months (B)